Allergan, Inc. v. Alcon Laboratories, Inc.
United States Court of Appeals for the Federal Circuit
324 F.3d 1322, 66 U.S.P.Q.2d 1225 (2003)
- Written by Sara Adams, JD
Facts
Alcon Laboratories, Inc.; Alcon Research, Ltd.; and Alcon Universal, Ltd. (Alcon) (defendants) as well as Bausch Lomb, Incorporated (defendant) filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (FDA). The ANDA sought authorization to produce and sell a generic form of brimonidine, an unpatented drug, for use in reducing eye pressure. Allergan, Inc., and Allergan Sales, Inc. (collectively, Allergan) (plaintiffs) held method-of-use patents for certain uses of brimonidine. Those uses did not include the treatment of eye pressure. Allergan filed an action in federal court for induced infringement against Alcon and Bausch Lomb. The district court granted summary judgment of noninfringement in favor of Alcon and Bausch Lomb. Allergan appealed. In opposing the appeal, Alcon and Bausch Lomb argued that the patent-listing provision, the patent-certification provision, and the remedies provision supported precluding liability for infringement if an ANDA sought approval for an unpatented and unapproved use.
Rule of Law
Issue
Holding and Reasoning (Per curiam)
Concurrence (Lin, J.)
Concurrence (Schall, J.)
What to do next…
Here's why 832,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,500 briefs, keyed to 994 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.